New drug combo aims to keep aggressive breast cancer from coming back
NCT ID NCT04254263
Summary
This study is testing whether adding a drug called pyrotinib to the standard one-year treatment (trastuzumab) helps prevent breast cancer from returning in women who still have cancer cells after initial chemotherapy and targeted therapy. It involves about 316 women with a specific type of breast cancer (HER2-positive) that is at a higher risk of recurrence. The goal is to see if this extra medication further lowers the chance of the cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITINGShanghai, Shanghai Municipality, 200127, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.